Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges, Nat. Rev. Genet, vol.12, pp.341-355, 2011. ,
Adeno-associated virus vector as a platform for gene therapy delivery, Nat. Rev. Drug. Discov, vol.18, pp.358-378, 2019. ,
Hemophilia B gene therapy with a high-specific-activity factor IX Variant, N. Engl. J. Med, vol.377, pp.2215-2227, 2017. ,
Safety and efficacy of gene transfer for Leber's congenital amaurosis, N. Engl. J. Med, vol.358, pp.2240-2248, 2008. ,
Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response, Nat Med, vol.12, pp.342-347, 2006. ,
Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy, N. Engl. J. Med, vol.377, pp.1713-1722, 2017. ,
Gene therapy with adeno-associated virus vector 5-human factor IX in adults with hemophilia B, 2017. ,
Long-term safety and efficacy of factor IX gene therapy in hemophilia B, N. Engl. J. Med, vol.371, 1994. ,
AAV5-Factor VIII Gene Transfer in Severe Hemophilia A, N. Engl. J. Med, vol.377, pp.2519-2530, 2017. ,
Onasemnogene Abeparvovec: First Global Approval, 2019. ,
Endgame: glybera finally recommended for approval as the first gene therapy drug in the European union, Mol. Ther, vol.20, pp.1831-1832, 2012. ,
, In CADTH Issues in Emerging Health Technologies, vol.1, p.11, 2016.
Emerging Issues in AAV-Mediated In Vivo Gene Therapy, Mol. Ther. Methods Clin. Dev, vol.8, pp.87-104, 2018. ,
URL : https://hal.archives-ouvertes.fr/hal-01812088
Adeno-associated virus antibody profiles in newborns, children, and adolescents, Clin Vaccine Immunol, vol.18, pp.1586-1588, 2011. ,
Update on the prevalence of serum antibodies (IgG and IgM) to adeno-associated virus (AAV), J Med Virol, vol.59, pp.406-411, 1999. ,
Neutralizing antibodies against adeno-associated virus examined prospectively in pediatric patients with hemophilia, Gene Ther, 2011. ,
Humoral immunity to AAV vectors in gene therapy: challenges and potential solutions, Discov. Med, vol.15, pp.379-389, 2013. ,
Unraveling the Complex Story of Immune Responses to AAV Vectors Trial After Trial. Hum, Gene Ther, vol.28, pp.1061-1074, 2017. ,
URL : https://hal.archives-ouvertes.fr/inserm-01798967
Human immunoglobulin inhibits liver transduction by AAV vectors at low AAV2 neutralizing titers in SCID mice, Blood, vol.107, pp.1810-1817, 2006. ,
Effects of transient immunosuppression on adenoassociated, virus-mediated, liver-directed gene transfer in rhesus macaques and implications for human gene therapy, Blood, vol.108, pp.3321-3328, 2006. ,
Life-long correction of hyperbilirubinemia with a neonatal liver-specific AAV-mediated gene transfer in a lethal mouse model of Crigler-Najjar Syndrome, Hum. Gene Ther, vol.25, pp.844-855, 2014. ,
Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors. Hum, Gene Ther, vol.21, pp.704-712, 2010. ,
Therapeutic plasma apheresis: Expertise and indications, Transfus. Apher. Sci, vol.58, pp.254-257, 2019. ,
A 10 Patient Case Report on the Impact of Plasmapheresis Upon Neutralizing Factors Against Adeno-associated Virus (AAV) Types 1, 2, 6, and 8, Mol. Ther, 2011. ,
Plasmapheresis Eliminates the Negative Impact of AAV Antibodies on Microdystrophin Gene Expression Following Vascular Delivery, Mol. Ther, 2013. ,
Preexisting immunity and low expression in primates highlight translational challenges for liver-directed AAV8-mediated gene therapy, Mol. Ther, vol.18, 1983. ,
Immunoadsorption enables successful rAAV5-mediated repeated hepatic gene delivery in nonhuman primates, Blood Adv, vol.3, pp.2632-2641, 2019. ,
Complications of apheresis, Semin. Dial, vol.25, pp.152-158, 2012. ,
Influence of Pre-existing Anti-capsid Neutralizing and Binding Antibodies on AAV Vector Transduction, Mol. Ther. Methods Clin. Dev, vol.9, pp.119-129, 2018. ,
URL : https://hal.archives-ouvertes.fr/hal-02377512
The pleiotropic effects of natural AAV infections on liver-directed gene transfer in macaques, Mol Ther, vol.18, pp.126-134, 2010. ,
Antigen-specific apheresis of pathogenic autoantibodies from myasthenia gravis sera, Ann. N. Y. Acad. Sci, vol.1132, pp.291-299, 2008. ,
In vitro assessment of a new ABO immunosorbent with synthetic carbohydrates attached to sepharose, Transpl. Int, vol.17, pp.666-672, 2005. ,
Antibodies against the VRT101 laminin epitope correlate with human SLE disease activity and can be removed by extracorporeal immunoadsorption, Rheumatol, vol.46, pp.1433-1437, 2007. ,
AAV8 virions hijack serum proteins to increase hepatocyte binding for transduction enhancement, Virology, vol.518, pp.95-102, 2018. ,
Direct interaction of human serum proteins with AAV virions to enhance AAV transduction: immediate impact on clinical applications, Gene Ther, vol.24, pp.49-59, 2017. ,
Humoral and cellular capsid-specific immune responses to adeno-associated virus type 1 in randomized healthy donors, J. Immunol, vol.188, pp.6418-6424, 2012. ,
Overcoming preexisting humoral immunity to AAV using capsid decoys, Sci. Transl. Med, vol.5, 2013. ,
Evaluation of Readministration of a Recombinant Adeno-Associated Virus Vector Expressing Acid Alpha-Glucosidase in Pompe Disease: Preclinical to Clinical Planning, Hum. Gene Ther. Clin. Dev, vol.26, pp.185-193, 2015. ,
Antigen-selective modulation of AAV immunogenicity with tolerogenic rapamycin nanoparticles enables successful vector re-administration, Nat. Commun, vol.9, 2018. ,
URL : https://hal.archives-ouvertes.fr/hal-02177709
Prevalence and pharmacological modulation of humoral immunity to AAV vectors in gene transfer to synovial tissue, Gene Ther, vol.20, pp.417-424, 2013. ,
Purification of recombinant adeno-associated virus type 8 vectors by ion exchange chromatography generates clinical grade vector stock, J. Virol. Methods, vol.121, pp.209-215, 2004. ,
Separation of adeno-associated virus type 2 empty particles from genome containing vectors by anion-exchange column chromatography, J. Virol. Methods, vol.140, pp.183-192, 2007. ,
Manipulation of the mechanical properties of a virus by protein engineering, Proc. Natl Acad. Sci. USA 105, pp.4150-4155, 2008. ,
Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy, Proc. Natl Acad. Sci. USA, vol.99, pp.11854-11859, 2002. ,
Therapeutic Apheresis in Immunologic Renal and Neurological Diseases, Ther. Apher. Dial, vol.21, pp.6-21, 2017. ,
Modulation of tolerance to the transgene product in a nonhuman primate model of AAV-mediated gene transfer to liver, Blood, vol.110, pp.2334-2341, 2007. ,
AAV capsid CD8 + T-cell epitopes are highly conserved across AAV serotypes, Mol. Ther. Methods Clin. Dev, vol.2, p.15029, 2015. ,
CD8(+) T-cell responses to adeno-associated virus capsid in humans, Nat. Med, vol.13, pp.419-422, 2007. ,
Enhanced exon-skipping induced by U7 snRNA carrying a splicing silencer sequence: Promising tool for DMD therapy, Mol. Ther, vol.17, pp.1234-1240, 2009. ,
Producing recombinant adeno-associated virus in foster cells: overcoming production limitations using a baculovirus-insect cell expression strategy. Hum, Gene Ther, vol.20, pp.807-817, 2009. ,
High AAV vector purity results in serotype-and tissue-independent enhancement of transduction efficiency, Gene Ther, vol.17, pp.503-510, 2010. ,
Determination of anti-adeno-associated virus vector neutralizing antibody titer with an in vitro reporter system, Hum. Gene Ther. Methods, 2015. ,